Enveric Biosciences, Inc. (ENVB): Nasdaq/NYSE listing notice — Enveric Biosciences receives Nasdaq deficiency notice for failing to meet minimum stockholders' equity requirement

Enveric Biosciences, Inc.

Stockholders' equity reported $2,435,646 as of Sept 30, 2023, below $2,500,000 minimum.
Company has until Jan 5, 2024 to submit a plan to regain compliance to Nasdaq.
If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.
Company does not meet alternative quantitative standards for continued listing.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Enveric Biosciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2023, reported stockholders’ equity of $2,435,646. As of the date of this Current Report on Form 8-K, the Company does not have a market value of listed securities of $35 million, or net income from continued operations of

View on SEC.gov

Browse all listing & compliance notices →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-042506

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.